Investors should be ready to buy the stock if it sees some pressure following the results, says Michael Landsberg, CIO of Landsberg Bennett Private Wealth.
These stocks offer rising dividends and the prospect of higher returns, Morgan Stanley says
Companies that step up their dividends could provide investors with some buffer against volatility.
Stanley Druckenmiller ramps up health-care stock exposure, gets back into Microsoft
The legendary investor, who has never had a down year, took a $100 million stake in Microsoft, after exiting the position in the third quarter of 2024.
CVS shares are breaking out to the upside after a 3-year bear market cycle, according to the charts
Chart strategist Katie Stockton breaks down the technical backdrop in CVS.
This has been one of the best earnings seasons on record, per Goldman Sachs
The earnings season is coming to a close, and Goldman Sachs says that companies’ performance this time is one of the best ever.
Best Stocks: Rounding out our biotech exposure with a big winner, one we missed and another we’re still early on
Josh Brown and Sean Russo break down three biotech names in the Best Stocks list.
UBS upgrades CVS to buy rating, sees further recovery ahead
UBS analyst Kevin Caliendo’s revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy chain.
Morgan Stanley says nuclear power is gaining momentum, recommends these stocks
The investment bank sees the U.S. adding 150 gigawatts of nuclear power by the middle of century.
Using options to trade Target earnings due out later this week
Options trader Michael Khouw breaks down an options trade on Target ahead of earnings.
Bitcoin sinks to $115,000 after hitting its newest record, as macro concerns spark liquidation wave
The crypto market tumbled to begin the week as heightened macro concerns triggered more than $500 million in long liquidations.